NCT00837200 · OUTCOME

Study Specific Measure (Number of Participants Taken Off Study)

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies · Source last updated 2017-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 16 weeks

Groups in this outcome

ODD Regimen

Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects. Oncaspar, Doxil, Decadron: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
ODD Regimen	13

Reported measurements

Due to Oncaspar-Related Toxicities

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
ODD Regimen	1	Not reported	Not reported	Not reported	Not reported

Not De to Oncaspar-Related Toxicities

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
ODD Regimen	12	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1
title
Due to Oncaspar-Related Toxicities
categories
measurements
group Id
OG000
value
12
title
Not De to Oncaspar-Related Toxicities

denoms

counts
group Id
OG000
value
13
units
Participants

groups

description
Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects. Oncaspar, Doxil, Decadron: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
id
OG000
title
ODD Regimen

param Type

NUMBER

reporting Status

POSTED

time Frame

16 weeks

title

Study Specific Measure (Number of Participants Taken Off Study)

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice